All In Biotech

Drug Trial Radar · NCT07388524

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 336 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

336

Planned (sponsor's estimate)

Start

Mar 2, 2027

Primary completion

Sep 30, 2032

Study completion Sep 30, 2032

Sponsor

Sponsor type
NIH
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.

Conditions

  • Lung Non-Small Cell Carcinoma

Interventions

  • AtezolizumabBiological

    Given IV

  • Atezolizumab and Recombinant Human HyaluronidaseBiological

    Given SC

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • Computed TomographyProcedure

    Undergo CT

  • Patient ObservationOther

    Undergo observation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survivalTime frame: From randomization to disease recurrence, second lung primary, or death, assessed up to 10 years

Locations

171 sites in 1 country. Site status is shown where the registry gives one.

  • Kaiser Permanente-Anaheim

    Anaheim, California · Recruiting

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California · Recruiting

  • Kaiser Permanente-Bellflower

    Bellflower, California · Recruiting

  • Tower Cancer Research Foundation

    Beverly Hills, California · Recruiting

  • Kaiser Permanente-Fontana

    Fontana, California · Recruiting

  • Kaiser Permanente South Bay

    Harbor City, California · Recruiting

  • Kaiser Permanente-Irvine

    Irvine, California · Recruiting

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente West Los Angeles

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente-Ontario

    Ontario, California · Recruiting

  • Kaiser Permanente - Panorama City

    Panorama City, California · Recruiting

  • Kaiser Permanente-Riverside

    Riverside, California · Recruiting

  • Kaiser Permanente-San Diego Zion

    San Diego, California · Recruiting

  • Kaiser Permanente-San Marcos

    San Marcos, California · Recruiting

  • Cedars-Sinai Cancer - Tarzana

    Tarzana, California · Recruiting

  • Torrance Memorial Physician Network - Cancer Care

    Torrance, California · Recruiting

  • Kaiser Permanente-Woodland Hills

    Woodland Hills, California · Recruiting

  • Beebe South Coastal Health Campus

    Millville, Delaware · Recruiting

  • Helen F Graham Cancer Center

    Newark, Delaware · Recruiting

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware · Recruiting

  • Beebe Health Campus

    Rehoboth Beach, Delaware · Recruiting

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho · Recruiting

  • Illinois CancerCare-Bloomington

    Bloomington, Illinois · Recruiting

  • Illinois CancerCare-Canton

    Canton, Illinois · Recruiting

  • Illinois CancerCare-Carthage

    Carthage, Illinois · Recruiting

  • John H Stroger Jr Hospital of Cook County

    Chicago, Illinois · Recruiting

  • Carle at The Riverfront

    Danville, Illinois · Recruiting

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinois · Recruiting

  • Decatur Memorial Hospital

    Decatur, Illinois · Recruiting

  • Carle Physician Group-Effingham

    Effingham, Illinois · Recruiting

  • Illinois CancerCare-Eureka

    Eureka, Illinois · Recruiting

  • Illinois CancerCare-Galesburg

    Galesburg, Illinois · Recruiting

  • Illinois CancerCare-Kewanee Clinic

    Kewanee, Illinois · Recruiting

  • Illinois CancerCare-Macomb

    Macomb, Illinois · Recruiting

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois · Recruiting

  • Carle BroMenn Medical Center

    Normal, Illinois · Recruiting

  • Carle Cancer Institute Normal

    Normal, Illinois · Recruiting

Showing 40 of 171 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.